Business Context and Reporting Period
Company: Bristol-Myers Squibb Company (BMS)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2007
Business Overview: BMS is a global biopharmaceutical company organized into three reportable segments: Pharmaceuticals (81% of sales), Nutritionals (13% of sales), and ConvaTec (6% of sales). The company focuses on the discovery, development, and sale of pharmaceuticals and health care products. In January 2008, the company completed the sale of its Medical Imaging business, which is reported as discontinued operations.
Key Financial Metrics
| Metric | 2007 | 2006 | Change |
|---|---|---|---|
| Net Sales | $19,348 million | $17,256 million | +12% |
| Net Earnings from Continuing Operations | $1,968 million | $1,422 million | +38% |
| Diluted EPS (Continuing Ops) | $0.99 | $0.73 | +36% |
| Operating Cash Flow | $3,153 million | $2,083 million | +51% |
| Total Assets | $26,172 million | $25,575 million | +2% |
| Long-Term Debt | $4,381 million | $7,248 million | -40% |
| Working Capital | $1,704 million | $3,806 million | -55% |
Note: Working capital decreased primarily due to the reclassification of Auction Rate Securities (ARS) to non-current assets and the reclassification of long-term debt to short-term borrowings.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 12% driven by a 46% increase in PLAVIX* sales (recovering from generic competition in 2006), strong growth in ABILIFY*, REYATAZ, and the SUSTIVA Franchise. This was partially offset by a 63% decline in PRAVACHOL sales due to generic competition.
- Profitability: Net earnings from continuing operations rose 38% to $1.97 billion. This increase occurred despite significant non-recurring charges, including a $275 million impairment on Auction Rate Securities (ARS), a $292 million charge for the Productivity Transformation Initiative (PTI), and a $230 million charge for acquired in-process R&D (Adnexus acquisition).
- Debt Reduction: Long-term debt decreased by $2.8 billion due to the repayment of the Floating Rate Bank Term Facility and the reclassification of debt due within one year to short-term borrowings.
- Investment Portfolio: The company recorded a $275 million pre-tax impairment charge on ARS holdings due to liquidity issues in credit markets, reclassifying the remaining ARS from marketable securities to non-current other assets.
Guidance, Outlook, and Risks
- Productivity Transformation Initiative (PTI): A three-year initiative launched in late 2007 targeting $1.5 billion in annual cost savings by 2010. Implementation costs are estimated at $0.9 billion to $1.1 billion, with $292 million incurred in 2007 and approximately $500 million expected in 2008.
- Dividend: The Board declared an 11% dividend increase in December 2007, raising the quarterly dividend to $0.31 per share (indicative annual dividend of $1.24 for 2008).
- Key Risks:
- PLAVIX* Litigation: Ongoing patent litigation with Apotex regarding PLAVIX*. While a District Court upheld the patent in June 2007, Apotex has appealed. A loss could result in renewed generic competition, materially impacting sales and cash flows.
- Investment Portfolio: Continued deterioration in credit markets could lead to additional impairments on the company's ARS holdings.
- Generic Competition: Significant risk of sales erosion for products losing exclusivity, particularly PRAVACHOL and potential future losses for PLAVIX* and ABILIFY*.
- Outlook: Management expects cash generated from operations, existing cash, and borrowings to be sufficient to cover working capital, capital expenditures (including a new biologics facility), and dividends.
Important Facts for Investor Verification
- PLAVIX* Patent Status: Verify the status of the Apotex appeal scheduled for March 2008, as the outcome determines the timeline for potential generic competition for the company's top-selling product.
- Auction Rate Securities (ARS): Confirm the current fair value and liquidity status of the remaining $419 million ARS portfolio, as further market deterioration could trigger additional impairment charges.
- PTI Execution: Monitor the realization of the projected $1.5 billion in cost savings and the timing of the remaining $500 million in restructuring charges expected in 2008.
- Medical Imaging Sale: Verify the final purchase price and net gain/loss on the sale of the Medical Imaging business to Avista Capital Partners, which closed in January 2008.
- Deferred Tax Assets: Assess the realizability of significant deferred tax assets ($1.14 billion foreign tax credits, $275 million research credits) which depend on future domestic taxable income.